# Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

> **NCT02694185** · NA · ACTIVE_NOT_RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 5269 (actual)

## Conditions studied

- Myocardial Ischemia
- Rheumatic Diseases

## Interventions

- **OTHER:** Caplan IVR

## Key facts

- **NCT ID:** NCT02694185
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2025-02-28
- **Target enrollment:** 5269 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694185, "Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02694185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*